INSURANCE/HEALTH: Provides relative to expand glucose-improving medications coverage to individuals based on body mass index (OR INCREASE EX See Note)

HB 869 requires Louisiana health insurance plans to cover FDA-approved injectable drugs for lowering glucose levels or treating obesity (BMI ≥30) when prescribed for prediabetes, gestational diabetes, or obesity. It applies to all new or renewed health plans starting January 1, 2026, with existing plans converting by January 1, 2027. Coverage must include these drugs if they're on the insurer's formulary, medically necessary, and prescribed by a healthcare provider. This directly affects Louisiana residents diagnosed with qualifying conditions who rely on these medications. The bill does not mandate coverage for all weight loss drugs, only those approved for specific medical uses.